Acceptance Criteria for Study Batches: When to Repeat


Published on 09/12/2025

Acceptance Criteria for Study Batches: When to Repeat

In the pharmaceutical industry, the assessment of extractables and leachables (E&L) from packaging materials, including single-use systems, is critical in ensuring the safety and efficacy of drug products. This step-by-step guide aims to outline the acceptance criteria for study batches in the context of E&L risk assessments, particularly focusing on the analytical evaluation threshold (AET), dose-based threshold (DBT) calculations, and container closure integrity (CCI) testing. Compliance with regulatory expectations set forth by bodies such as the FDA, European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) is paramount for pharmaceutical success.

Step 1: Understanding Extractables and Leachables

Extractables and leachables consist of chemical compounds that can migrate from packaging materials into pharmaceutical products. Understanding the differentiation between extractables and leachables is essential:

  • Extractables: These are substances that can be extracted from a material under specific conditions, typically more aggressive than those encountered in actual use.
  • Leachables: These are components that have leached into the drug product during normal storage and use conditions.

To ensure drug safety and compliance, a detailed E&L risk assessment should be conducted based on the materials used in packaging and their anticipated interactions with the drug product. This risk assessment begins with identifying all potential extractables and evaluating their potential leachability.

Step 2: Conducting a Robust Analytical Evaluation Threshold (AET) Analysis

The AET is a critical value that determines the minimum concentration at which leachable substances could potentially impact product safety. To determine the AET, follow these guidelines:

  1. Identify the Compound: Review safety data sheets (SDS) for all materials used in the container closure systems, along with any relevant literature.
  2. Calculate the AET: Utilize statistical methods to ascertain the AET based on safety thresholds for each compound, as defined by regulatory standards. It is advisable to apply the risk assessment guidance set by USP.
  3. Document Justification: Maintain thorough records justifying the use of specific AET values in your risk assessment documentation.

In some cases, particularly when multiple materials are involved, it may be necessary to use a cumulative approach to determine how various extractables interact.

Step 3: Dose-Based Threshold (DBT) Calculation

The DBT is used to establish acceptable limits for leachables based on the anticipated patient exposure to the drug product. It is calculated based on how much of the material is expected to leach into the drug product and the maximum allowable dose. Follow these steps for DBT calculation:

  1. Determine Patient Exposure: Assess the dosage and frequency of administration to establish what a typical patient would experience.
  2. Define Acceptable Limits: Utilize established toxicological reference values to define safe limits for leachables, often informed by regulatory bodies. Common references include the PQRI guideline.
  3. Calculate DBT: Using the patient exposure data, apply the relevant toxicological thresholds to calculate the DBT, ensuring alignment with the FDA’s Process Validation guidance.

This controversial but necessary calculation forms the basis for further analytical testing and determination of total acceptable limits for your study batches.

Step 4: Setting Acceptance Criteria for Analytical Testing

Once AET and DBT values have been established, these thresholds serve as foundational elements for defining acceptance criteria for analytical methods used in E&L testing. Key considerations include:

  • Method Validation: Ensure analytical methods employed for the detection of extractables and leachables are validated according to regulatory expectations set forth by EU GMP Annex 1.
  • Acceptance Criteria: Define specific acceptance criteria based on the calculated AET and DBT for the study batches. For example, if an extractable’s concentration is below the AET, it may be considered as meeting criteria.

These criteria not only support a rigorous testing protocol but also defend the integrity of your data during regulatory inspections.

Step 5: Conducting Container Closure Integrity (CCI) Testing

CCI testing is essential to verify that the packaging system effectively protects the drug product from potential leachables while maintaining its integrity. The following points must be addressed:

  1. Choose Appropriate CCI Testing Methods: Depending on your product and packaging, methods may include helium leak testing, dye ingress, or pressure decay testing.
  2. Design the Study: Conduct studies that simulate real-world conditions to assess the packaging system’s performance over its intended shelf life.
  3. Establish Acceptance Criteria for CCI: The results must demonstrate reliability in preventing leachables from contaminating the drug product. Regulatory guidelines will inform the acceptable limits.

Regular CCI testing must be incorporated into both routine production practices and studies on new or modified packaging systems to validate containment.

Step 6: Addressing Failures and Repeating Studies

Instances may arise where a study batch does not meet the established acceptance criteria for AET, DBT, or CCI. Appropriately addressing such failures is crucial:

  • Investigate the Cause: Conduct a thorough investigation to ascertain why the criteria were not met. It may involve reviewing manufacturing practices or reevaluating the materials used.
  • Implement Corrective Actions: Address any identified issues by modifying processes, retraining staff, or revising applicable methods.
  • Repeat Testing: Before re-issuing the product, perform repeat testing on newly manufactured batches to ensure alignment with acceptance criteria.

Failing to meet established criteria necessitates transparency and thorough documentation of actions taken, adhering to both US and EU regulations that emphasize risk assessment and the continuous improvement of pharmaceutical practices. This is particularly vital for maintaining compliance with standards outlined by EMA and enhancing patient safety.

Conclusion: Ensuring Compliance Through Rigorous Validation

In conclusion, establishing and adhering to acceptance criteria for study batches in the context of E&L is imperative for regulatory compliance and patient safety. Implementing structured methods for AET, DBT, and CCI testing creates a defensible framework for your quality assurance processes. By ensuring that your methodologies align with regulatory guidelines such as those provided by the FDA, EMA, and MHRA, you empower your organization to assert compliance and support the successful launch and use of pharmaceutical products globally.

This guide serves as a comprehensive overview for pharma professionals, clinical operations, and regulatory affairs personnel. For continued adherence to standards and evolving frameworks governing E&L, further education and familiarity with regulatory updates are recommended.